Genelux (NASDAQ:GNLX) is a biopharmaceutical company dedicated to pioneering innovative treatments for cancer patients. It centers its efforts on developing oncolytic viral therapies, a cutting-edge approach that leverages viruses to selectively kill cancer cells while sparing healthy tissues. Genelux's project portfolio highlights its flagship candidate, Olvi-Vec, designed for the treatment of solid tumor cancers through direct injection into tumors, showcasing promising clinical trial outcomes. With a steadfast commitment to transforming cancer treatment, Genelux's objectives include advancing its clinical programs, expanding its therapeutic pipeline, and ultimately improving patient outcomes by delivering safer and more effective cancer therapies.